Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Amyloidosis Channel on VJHemOnc is an independent medical education platform, supported with funding from Prothena (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

ISA 2020 | RNAi therapeutics for ATTR amyloidosis

Mathew Maurer • 23 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Mathew Maurer, MD, Columbia University, New York, NY, discusses the use of RNAi therapeutics for ATTR amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mathew Maurer

Heart transplantation in ATTR amyloidosis 2:09
Heart transplantation in ATTR amyloidosis
Mathew Maurer • 16 Sep 2020
DISCOVERY: cardiac amyloidosis screening study 1:53
DISCOVERY: cardiac amyloidosis screening study
Mathew Maurer • 3 Sep 2020

Related Videos

Refining the diagnosis and classification of CMML 6:25
Refining the diagnosis and classification of CMML
Guillermo Montalban-Bravo et al. • 20 Sep 2025
Improving the diagnosis of amyloidosis: advice that can be applied in practice 2:48
Improving the diagnosis of amyloidosis: advice that can be applied in practice
Gareth Morgan • 18 Sep 2025
Ongoing research in gray zone lymphoma 1:07
Ongoing research in gray zone lymphoma
Kieron Dunleavy • 4 Sep 2025
Insights into gray zone lymphoma: a rare subtype of NHL 1:14
Insights into gray zone lymphoma: a rare subtype of NHL
Kieron Dunleavy • 4 Sep 2025
The content of VJHemOnc is intended for healthcare professionals